Quininib is primarily investigated for its potential in cancer therapy and ocular diseases, particularly in targeting angiogenesis, the process by which new blood vessels form from pre-existing vessels. This is crucial in cancer treatment as tumors require a blood supply to grow and metastasize, and in conditions like wet age-related macular degeneration (AMD) where abnormal blood vessel growth in the eye leads to vision loss. Quininib works by inhibiting specific pathways involved in angiogenesis, such as VEGFR2 tyrosine kinase, thereby starving tumors or ocular neovessels of necessary nutrients and oxygen. Research has shown its efficacy in preclinical models of various cancers, including colorectal and ovarian cancer, as well as in models of retinal and choroidal neovascularization. Additionally, its anti-inflammatory properties are being explored for potential applications in treating inflammatory diseases, offering a dual therapeutic approach. Ongoing studies aim to optimize its efficacy and safety profile for clinical use, with Quininib serving as a lead molecule for designing new, more effective drugs with reduced side effects.